Lomitapide in the long-term real-world management of HoFH – effectiveness, tolerability, and hepatic safety from the Pan-European study

• J. Cegla,
• L. d’Erasmo,
• K. Steward,
• A. di Costanzo,
• E. Boersma,
• M. Arca,
• J. Roeters van Lennep

Affiliations

J. Cegla

Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK

L. d’Erasmo

Department of Internal Medicine and Clinical Specialties, Sapienza University of Rome, Rome, Italy

K. Steward

Department of Internal Medicine, Erasmus MC, University Medical Centre Rotterdam, the Netherlands

A. di Costanzo

Department of Internal Medicine and Clinical Specialties, Sapienza University of Rome, Rome, Italy

E. Boersma

Department of Cardiology, Erasmus MC, University Medical Centre Rotterdam, the Netherlands

M. Arca

Department of Internal Medicine and Clinical Specialties, Sapienza University of Rome, Rome, Italy

J. Roeters van Lennep

Department of Internal Medicine, Erasmus MC, University Medical Centre Rotterdam, the Netherlands